HIV vaccine triggers broadly neutralizing antibodies in 44% of primates

HIV vaccine triggers broadly neutralizing antibodies in 44% of primates. A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists and IAVI has the potential to protect humans from developing HIV infection and AIDS.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists and IAVI has the potential to protect humans from developing HIV infection and AIDS. This HIV vaccine is the first to generate a high number of "broadly neutralizing" virus-fighting antibodies in primates.

• Ponto de atenção: vaccine.
• Ponto de atenção: triggers.
• Ponto de atenção: broadly.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.